Related Experiment Video
Updated: Jul 25, 2025
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.3K
Association of CD47 Expression with Clinicopathologic Characteristics and Survival Outcomes in Muscle Invasive
Zin W Myint1,2, Zena Chahine1,2, Rani Jayswal2
1Division of Medical Oncology, Department of Internal Medicine, University of Kentucky, Lexington, KY 40536, USA.
Journal of Personalized Medicine
|June 28, 2023
Summary
CD47 expression is not a predictive marker in muscle invasive bladder cancer (MIBC). However, CD47 is present in nearly half of MIBCs, warranting further investigation into anti-CD47 therapies.
Area of Science:
- Oncology
- Immunology
- Urology
Background:
- CD47 is an antiphagocytic molecule crucial for immune surveillance.
- Tumors evade immune detection by upregulating CD47.
- Anti-CD47 therapy is under clinical investigation for various cancers.
Purpose of the Study:
- To investigate the expression and prognostic significance of CD47 in muscle invasive bladder cancer (MIBC).
- To determine if CD47 expression correlates with clinicopathological parameters and survival outcomes in MIBC patients.
Main Methods:
- Retrospective study of 87 MIBC patients undergoing transurethral resection of bladder tumor (TURBT) and radical cystectomy (RC).
- CD47 expression assessed by immunohistochemistry (IHC) in TURBT and RC specimens.
- Statistical analysis using chi-squared tests and Kaplan-Meier method to evaluate associations with clinicopathological parameters and survival.
Main Results:
- CD47 expression was detected in 44% of TURBT samples.
- No significant association found between CD47 levels and clinicopathological parameters or overall survival (OS).
- Older age (>60), non-response to neoadjuvant chemotherapy (NAC), and advanced stage (≥3) were associated with worse OS.
Conclusions:
- CD47 expression is not a prognostic or predictive marker in MIBC.
- The presence of CD47 in a significant portion of MIBCs suggests potential for anti-CD47 therapy.
- Further research is needed to explore anti-CD47 therapy and the impact of NAC on CD47 levels in MIBC.
